Reopening America

Latest Episodes:

Pfizer and Moderna Vaccines Tested in Real-Life Conditions With Front Line Workers Show 90% Effectiveness Against COVID Mar 30, 2021

Show notes

A new study conducted by the CDC that followed about 4,000 health care personnel, police, firefighters, and other essential workers found that under real-life conditions, both the Pfizer and Moderna vaccines are 90% effective after your second dose. Good news that is significant because these were all front-line workers who are more likely to be exposed to the virus. Lena Sun, health reporter at The Washington Post, joins us for more on vaccine effectiveness.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

As Schools Closed During the Pandemic, the Mental Health of Students Also Suffered Mar 29, 2021

Show notes

As schools shut down for almost a year in many cases during the pandemic, the mental health of students greatly suffered. According to a Reuters survey of school districts, 74% reported multiple indicators of mental health stresses among students and 57% of responding districts said that teachers were also seeking assistance. Michael Pell, data journalist at Reuters, joins us for how the pandemic did more damage to our students than just getting behind on schoolwork.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

After Adjusting for New Data, AstraZeneca Vaccine Is 76% Effective Against COVID-19 Mar 26, 2021

Show notes

AstraZeneca and their vaccine has been on a rollercoaster ride this week as we learned that their shot is 76% effective against symptomatic Covid-19. On Monday it was 79%, then U.S. officials said they were using outdated data, and finally came back with the correction. Karen Weintraub, healthcare reporter at USA Today, joins us for the difficult rollout of this vaccine.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Why the Johnson & Johnson Vaccine Rollout Has Been So Bumpy Mar 25, 2021

Show notes

We currently have three great vaccine options out there, but the rollout for one seems to be a little bumpier than the others. The Johnson & Johnson vaccine is just not reaching as many arms as the others. Only about half of the doses that have been distributed, have been administered. Some officials believe that states may be holding back some shots to bank enough to reach underserved communities, but some states representatives say they are using all available doses as they come. Erin Banco, healthcare reporter at Politico, joins us for why the J&J vaccine might not be reaching more people.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Efficacy of AstraZeneca Vaccine Called Into Question After Using Outdated Data Mar 24, 2021

Show notes

From good news to questions and concerns. AstraZeneca released details from its U.S. trials that their vaccine is 79% effective against Covid-19. Then, hours later, federal officials said that they might have used outdated information and was missing a month’s worth of data. AstraZeneca said it would release more data soon, but the damage may have already been done, another misstep in the rollout. Karen Weintraub, health reporter at USA Today, joins us for the latest.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

We May Soon Have Another Vaccine Available as AstraZeneca U.S. Trials Show 79% Effectiveness Against COVID Mar 23, 2021

Show notes

Good news as we may soon have another vaccine available to us. AstraZeneca and its partner, Oxford University, have released information about their clinical trials in the U.S. and found their vaccine is safe and prevents 79% of symptomatic cases of Covid-19. It also reduced severe cases and hospitalizations by 100%. There has been recent concern of blood clots associated with the vaccine in Europe, but the trials showed that no cases of that in the U.S. Karen Weintraub, health reporter at USA Today, joins us for more.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Pandemic Housing Boom Beneficial to Homeowners, Creates High Competition for Buyers Mar 20, 2021

Show notes

The pandemic has created a housing boom, but it’s different from the last time. Residential home prices are hitting highs that we haven’t seen since 2006. The big winners are people who already own homes because they can take advantage of lower mortgage rates, but on the other side, competition is stiff because of low supply. Nicole Friedman, reporter at the WSJ, joins us to talk about the crazy housing market.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Moderna Will Begin Testing Its COVID-19 Vaccine on Children Mar 19, 2021

Show notes

Moderna announced this week that they will begin testing their Covid vaccine on children aged 6 months to 11 years. This is the next piece of the puzzle to widen the mass vaccination campaign beyond adults. If all goes well, health officials believe that junior high and high school students could get their shots in the fall and elementary school students early next year. Peter Loftus, healthcare reporter at the WSJ, joins us for more.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Focus Group Shines Light on What Could Win Over Vaccine Hesitant GOP Voters Mar 18, 2021

Show notes

The White House is planning a wide-reaching campaign at getting those that are skeptical of the vaccines on board. It will be targeting young people, people of color, and conservatives. A recent focus group shows that to target some GOP voters, it will be best to keep politics out of it and provide as much information as possible so they can make informed decisions. Dan Diamond, national health reporter at The Washington Post, joins us for how to win over some vaccine skeptics.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Which Vaccine Do You Want? The Differences Are Small, but They Do Exist Mar 17, 2021

Show notes

Which vaccine are you getting? For now, the experts are clear that the best vaccine to get is the first one that is available to you. But if you had your choice as supply goes up, which would you get? There are concerns about side effects, effectiveness, and immunity and those differences are small, but they do exist. Elizabeth Weise, national correspondent at USA Today, joins us for what to know about the available vaccines.

Next, the White House is planning a wide-reaching campaign at getting those that are skeptical of the vaccines on board. It will be targeting young people, people of color, and conservatives. A recent focus group shows that to target some GOP voters, it will be best to keep politics out of it and provide as much information as possible so they can make informed decisions. Dan Diamond, national health reporter at The Washington Post, joins us for how to win over some vaccine skeptics.

Finally, in a good sign of a recovering economy, the hotel industry is starting to regain some footing after its worst year ever. Americans are getting the itch to travel again and there are some good indicators for the leisure and hospitality industry. They are hiring again, getting advanced bookings, and seeing stock shares rise. Peter Grant, reporter at the WSJ, joins us for what we hope is a hotel rebound.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected